2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2023.06.012

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (6): 815-818.doi: 10.3969/j.issn.1672-5069.2023.06.012

2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨^*

丁晓洁, 张永明, 宋海燕, 王文平, 宋洁, 撒小军, 邹永红

230031 合肥市安徽省第二人民医院内分泌科(丁晓洁,张永明,王文平,宋洁,邹永红,撒小军);解放军联勤保障部队第901医院感染病科(宋海燕)

收稿日期:2023-02-17 出版日期:2023-11-10 发布日期:2023-11-20
通讯作者: 张永明,E-mail:zym670108@163.com
作者简介:丁晓洁,女,39岁,医学硕士,副主任医师。E-mail:114361734@qq.com
基金资助:
^* 安徽省高等学校科研基金资助项目(编号:2022AH052335)

Prediction of NAFLD in patients with type 2 diabetes mellitus by NLR and PLR: A preliminary study

Ding Xiaojie, Zhang Yongming, Song Haiyan, et al

Department of Endocrinology, Second Provincial People＇s Hospital,Hefei 230031, Anhui Province,China

Received:2023-02-17 Online:2023-11-10 Published:2023-11-20

摘要/Abstract

摘要： 目的研究应用中性粒细胞/淋巴细胞比值(NLR)和血小板/淋巴细胞比值(PLR)评估2型糖尿病(T2DM)患者合并非酒精性脂肪性肝病(NAFLD)的效能。方法 2021年1月～2022年10月安徽省第二人民医院内分泌科收治的T2DM患者110例和T2DM合并NAFLD患者121例,使用超声检查诊断脂肪肝,应用二元Logistic回归分析影响T2DM合并NAFLD的危险因素,应用受试者工作特征曲线(ROC)预测NLR和PLR评估T2DM合并NAFLD的效能。结果 T2DM合并NAFLD组体质指数(BMI)为(25.4±3.5)kg/m²,显著大于T2DM组【(23.2±3.1)kg/m²,P<0.05】,而病程为5.0(2.0,8.0)年,显著短于T2DM组【8.0(3.0,13.0)年,P<0.05】;T2DM合并NAFLD组血清ALT、AST、GGT、UA、TG和TC水平均显著大于T2DM组,而血清HDL-C水平则显著低于T2DM组,差异有统计学意义(P＜0.05);T2DM合并NAFLD组外周血淋巴细胞计数为(1.7±0.4)×10⁹/L,显著低于T2DM组【(2.2±0.6)×10⁹/L,P<0.05】,而NLR和PLR分别为(2.4(1.8,3.2))和(126.1(93.3,157.8)),均显著大于T2DM组【分别为1.5(1.2,2.3)和89.6(66.9,116.5),P<0.05】;采用二元Logistic回归分析,结果显示BMI、NLR和PLR是2型糖尿病合并NAFLD的危险因素(P＜0.05);经ROC曲线分析,结果显示NLR和PLR预测T2DM合并NAFLD的灵敏度和特异度分别为64.5%和75.0%,和71.9%和65.4%。结论应用简单的血液学指标NLR和PLR可以帮助初步筛选T2DM患者是否合并NAFLD,值得进一步研究。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 中性粒细胞/淋巴细胞比值, 血小板/淋巴细胞比值, 诊断

Abstract: Objective The study was conducted to assess the prediction of non-alcoholic fatty liver diseases (NAFLD) in patients with type 2 diabetes mellitus (T2DM) by neutrophil-to-lymphocyte ratio(NLR) and platelet-to-lymphocyte ratio(PLR) . Methods 110 patients with T2DM and 121 patients with T2DM and NAFLD were included in the Department of Endocrinology, Second Provincial People's Hospital between January 2021 and October 2022, and the NAFLD was proven by ultrasonography. The blood routine was checked-up. The risk factors of T2DM with NAFLD were assessed by multivariate Logistic analysis, and predictive efficacy was evaluated by ROC curve. Results The body mass index in patients with T2DM and concomitant NAFLD was (25.4±3.5)kg/m², much greater than [(23.2±3.1)kg/m², P<0.05], while the course of disease was 5.0(2.0, 8.0)yr, significantly shorter than [8.0(3.0, 13.0)yr, P<0.05] in patients with T2DM; serum alanine aminotransferase, aspartate aminotransferase, glutamyl transpeptidase, uric acid, triglyceride and total cholesterol levels in patients with T2DM and NAFLD were all significantly greater than in patients with T2DM, while serum high density lipoprotein cholesterol level was much lower than in patients with T2DM (P＜0.05); the blood lymphocyte count in patients with T2DM and NAFLD was (1.7±0.4)×10⁹/L, much lower than [(2.2±0.6)×10⁹/L, P<0.05], while the NLR and PLR were (2.4(1.8, 3.2)) and (126.1(93.3, 157.8)), both significantly greater than [1.5(1.2, 2.3) and 89.6(66.9, 116.5), respectively, P<0.05] in patients with T2DM; the Logistic analysis showed that the BMI, NLR and PLR were the risk factors for coincidence of NAFLD in patients with T2DM (P＜0.05); the ROC analysis demonstrated that the sensitivities and the specificities by NLR and PLR in prediction of NAFLD in patients with T2DM were 64.5% and 75.0%, and 71.9% and 65.4%, respectively. Conclusion The surveillance of NLR and PLR, easily accessible, in patients with T2DM might help screen preliminarily NAFLD, and warrants further clinical investigation.

Key words: Non-alcoholic fatty liver diseases, Type 2 diabetes mellitus, Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio, Diagnosis

丁晓洁, 张永明, 宋海燕, 王文平, 宋洁, 撒小军, 邹永红. 2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 815-818.

Ding Xiaojie, Zhang Yongming, Song Haiyan, et al. Prediction of NAFLD in patients with type 2 diabetes mellitus by NLR and PLR: A preliminary study[J]. Journal of Practical Hepatology, 2023, 26(6): 815-818.

参考文献

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2):177-186.
[2] Younossi ZM. Non-alcoholic fatty liver disease–A global public health perspective. J Hepatol,2019,70(3):531-544.
[3] Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut,2017,66(66):1138-1153.
[4] 刘傲雪,周翔海,张秀英,等.非酒精性脂肪肝的危险因素讨论.中国临床医生杂志,2021,49(2):165-169.
[5] Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med,2020,18(1):360.
[6] Gong P, Liu Y, Chen G, et al. The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ration with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke. J Neuroinflammation,2021,18(1):51.
[7] Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio(NLR) and platelet-to-lymphocyte ratio(PLR) as prognostic markers in patients with non-small cell lung cancer(NSCLC) treated with nivolumab. Lung Cancer,2017,111:176-181.
[8] Balta S, Ozturk C. The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets,2015,26(7):680-681.
[9] Karakaya S,Altay M,Kaplan EF,et al. The neutrophil-lymphocyte ratio and its relationship with insulin resistance in obesity. Turk J Med Sci,2019,49(1):245-248.
[10] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版).中华糖尿病杂志,2021,13(4):317-411.
[11] Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology,1998,114(4):842-845.
[12] Fang YL, Chen H, Wang CL, et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model".World J Gastroenterol,2018,4(27):2974-2983.
[13] Hu M, Phan F, Bourron O, et al.Steatosis and NASH in type 2 diabetes.Biochimie,2017,143:37-41.
[14] Chacko KR,Reinus J.Extrahepatic complications of nonalcoholic fatty liver disease.Clin Liver Dis,2016,20(2):387-401.
[15] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Hepatology,2019,69(6):2672-2682.
[16] Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology, 2001,34(4):738-744.
[17] Kahraman NK, Cuneyt C, Kocak FE, et al. Predictive value of neutrophil to lymphocyte ratio in the severity of non-alcoholic fatty liver disease among type 2 diabetes patients. Acta Gastro Enterologica Belgica,2016,79(3):295-300.
[18] 吴仪伟,武攸,崔晓艳,陈琰. PLR、NLR与T2DM合并代谢相关脂肪性肝病肝纤维化的关系. 临床与病理杂志,2022,42(7):1615-1621.
[19] Elgazar Carmon V, Rudich A, Hadad N, et al. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J Lipid Res,2008,49(9):1894-1903.
[20] Zimmermann E, Anty R, Tordjman J, et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol,2011,55(3):660-665.

2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨^*

Prediction of NAFLD in patients with type 2 diabetes mellitus by NLR and PLR: A preliminary study

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曾静, 范建高. 代谢相关脂肪性肝病自然史研究进展[J]. 实用肝脏病杂志, 2023, 26(6): 769-772.
[2]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[3]	卢蓉, 李慧, 张超, 邵正健, 罗大光. 甘油三酯/葡萄糖指数预测非酒精性脂肪性肝病严重程度效能研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 805-810.
[4]	邵孝如, 周筱, 葛颖颖. ¹⁸F-FDG摄取量诊断非酒精性脂肪性肝病患者罹患冠状动脉粥样硬化性心脏病探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 811-814.
[5]	侯义林, 曹风华, 纪小燕, 蔡燕. 非酒精性脂肪性肝病患者肠道菌群及血清IL-17和INF-γ水平变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 819-822.
[6]	王卓雅, 吴洋鹏, 黄益桃. 还原型谷胱甘肽联合护肝清脂片治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 823-826.
[7]	阎道博, 朱海超, 闪海霞. 瞬时弹性成像联合APRI诊断自身免疫性肝炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 831-834.
[8]	田宇, 陈燕, 曹佳非, 周晓倩. 肝硬化并发肝肾综合征患者U-mAl及外周血NLR和血清NGAL水平变化研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 859-862.
[9]	刘欢, 陈鹏, 蒯文涛, 徐亮. 肝脏硬度测定、血小板计数/脾厚比值和脾静脉直径预测肝硬化并发食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 867-870.
[10]	贺梅年, 赵思佳, 田智超, 何秀英, 巴正武. 超声半定量评分结合弹性成像诊断慢性乙型肝炎患者早期肝硬化临床价值分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 871-874.
[11]	莫春明, 黄德佳, 韦惠章, 罗江伟. TACE术治疗的原发性肝癌患者血清IL-33水平变化及其对发热的鉴别意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 887-890.
[12]	周莉, 丁云清, 袁凤英, 陈竹, 冯志伟. 超声造影判断乙型肝炎肝硬化患者肝内占位性病变性质价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 903-906.
[13]	张蕊, 时倩倩, 王仲秋. DCE-MRI、DWI和MRCP联合诊断肝外胆管癌临床价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 923-926.
[14]	韩仕杉, 赵彩彦. Betatrophin与非酒精性脂肪性肝病[J]. 实用肝脏病杂志, 2023, 26(6): 930-933.
[15]	黄柏盛, 区蓝芯, 张莹洁, 方梦冰, 施梅姐, 黎胜, 萧焕明. FibroScan联合GPR、APRI和FIB-4诊断血清ALT正常的慢性HBV感染者肝纤维化价值分析^*[J]. 实用肝脏病杂志, 2023, 26(5): 618-621.